Latest News and Press Releases

Zug, Switzerland, March 29, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

Initiated second Phase 1 clinical trial with intranasal betahistine Preparing for health authority discussions of regulatory pathway for AM-111 program Analyses of Keyzilen® trial outcomes...

Zug, Switzerland, March 13, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

Zug, Switzerland, February 26, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Proposed capital restructuring to ensure compliance with Nasdaq minimum bid price rule contingent on Company's share price development Alain Munoz proposed as new member of the Board of the...

Single dose animal study demonstrates 5 to 35 times higher bioavailability of intranasal betahistine relative to oral betahistine Bioavailability of intranasal betahistine in humans estimated...

  Zug, Switzerland, January 29, 2018 - Auris Medical Holding AG ("Auris Medical", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

Further analyses from HEALOS Phase 3 clinical trial support AM-111's otoprotective effects in patients with profound acute hearing loss Clinically and statistically significant improvement in...

Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

HEALOS trial did not meet primary efficacy endpoint  in overall study population Clinically and statistically significant improvement in subpopulation of patients with profound acute hearing...